Filtered By:
Cancer: Lymphoma
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 106 results found since Jan 2013.
Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies
CONCLUSION: Serious infection and IFI rates are high but similar to those previously described. Risk factors for serious infection included allo-HSCT and corticosteroid use. Targeted antimicrobial prophylaxis should be evaluated in prospective studies in patients on ibrutinib to reduce serious infections and IFI.PMID:37675967 | DOI:10.1093/ajhp/zxad210
Source: American Journal of Health-System Pharmacy : AJHP - September 7, 2023 Category: Drugs & Pharmacology Authors: Kenneth Tham Stacy Prelewicz Sara deHoll Deborah M Stephens Carlos A Gomez Source Type: research
Systematic Review - Type B insulin Resistance with Isolated Hypoglycemia and Supressed Insulin
CONCLUSIONS: Isolated hypoglycemia with low insulin forms a rare subgroup of type B insulin resistance. These patients lack the common characteristics of hyperinsulinemic hypoglycemia and hyperglycemia/insulin resistance. Furthermore, whilst coexisting autoimmune disease is commonly observed, there is potentially an association with aggressive lymphoma, the onset of which may be delayed.PMID:37552775 | DOI:10.1210/clinem/dgad467
Source: The Journal of Clinical Endocrinology and Metabolism - August 8, 2023 Category: Endocrinology Authors: Natasha Brown Marianne S Elston Source Type: research
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
In conclusion, Pembrolizumab with Vorinostat was tolerable and produced responses in relapsed/refractory B-cell NHL, with particularly notable efficacy in PMBL.PMID:37470137 | DOI:10.3324/haematol.2023.283002
Source: Haematologica - July 20, 2023 Category: Hematology Authors: James Godfrey Matthew Mei Lu Chen Joo Y Song Victoria Bedell Elizabeth Budde Saro Armenian Sandrine Puverel Liana Nikolaenko Robert Chen Shari Daniels Neena Kennedy Lacolle Peters Steven T Rosen Stephen J Forman Leslie L Popplewell Larry W Kwak Alex F Her Source Type: research
Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
Oncologist. 2023 Jun 7:oyad155. doi: 10.1093/oncolo/oyad155. Online ahead of print.ABSTRACTMogamulizumab is being increasingly prescribed for the treatment of T-cell lymphomas (MF/SS/ATLL). We conducted a retrospective cohort study to identify muscular immune-related adverse events (irAEs) associated with mogamulizumab in patients with T-cell lymphoma followed at Dana-Farber Cancer Institute from January 2015 to June 2022. We identified 5 cases of mogamulizumab-associated myositis and/or myocarditis (MAM/Mc), 2 additionally affected by myasthenia gravis, among 42 patients with T-cell lymphoma. Three cases experienced -moga...
Source: The Oncologist - June 7, 2023 Category: Cancer & Oncology Authors: Cesar A Virgen Jeffrey A Sparks Anju Nohria Meabh J O'Hare Amrita Goyal Jordan T Said Marianne Tawa Nicole R LeBoeuf Thomas S Kupper David C Fisher Cecilia Larocca Source Type: research
Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
Ther Adv Med Oncol. 2023 May 29;15:17588359231175438. doi: 10.1177/17588359231175438. eCollection 2023.ABSTRACTLung cancer is the second most common cancer and the most common cause of cancer-related death in the United States. Brain metastases (BM) are detected in 21% of patients with lung cancer at the time of diagnosis and are the sole metastatic site in 35% of patients with stage IV disease. The best upfront therapy for non-small-cell lung cancer depends on both tumor programmed death 1 ligand-1 (PD-L1) expression and the presence or absence of a targetable genetic alteration in genes such as epidermal growth factor re...
Source: Adv Data - June 5, 2023 Category: Epidemiology Authors: Ross D Merkin Veronica L Chiang Sarah B Goldberg Source Type: research
Influence of corticosteroid treatment on CXCR4 expression in DLBCL
CONCLUSION: Overall, corticosteroid treatment (Dex/Pred) consistently induced an upregulation of CXCR4 expression DBLCL cells in vitro, albeit in a very cell line-dependent manner. For the cell line with the most pronounced Dex-induced CXCR4 upregulation, OCI-LY1, the in vitro findings were corroborated by an in vivo biodistribution study. This confirms that at least the corticosteroid component of stabilizing chemotherapy regimens in DLBCL patients prior to [177Lu]Lu-PentixaTher RLT does not lead to downregulation of the molecular target CXCR4 and may even have a beneficiary effect. However, further studies are needed to ...
Source: Cell Research - May 10, 2023 Category: Cytology Authors: Sebastian Martin David Viertl Anna Janz Stefan Habringer Ulrich Keller Margret Schottelius Source Type: research
Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
Int J Hematol. 2023 Apr 24. doi: 10.1007/s12185-023-03607-w. Online ahead of print.ABSTRACTAnti-SARS-CoV-2 vaccines were developed in response to the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the BNT162b2 mRNA vaccine is effective, adverse effects have been reported. Here, we report a case of extranodal NK/T-cell lymphoma, nasal type (ENKL), of the left arm following BNT162b2 mRNA vaccination. A 73-year-old male presented with a lump in the left arm, which was the site where he received the BNT162b2 mRNA vaccine 3 months prior. He was treat...
Source: International Journal of Hematology - April 24, 2023 Category: Hematology Authors: Takuto Tachita Takenori Takahata Satoru Yamashita Toru Ebina Kosuke Kamata Kazufumi Yamagata Yoshiko Tamai Hirotake Sakuraba Source Type: research
